fulvestrant has been researched along with Endocrine Gland Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdulkareem, NM; Bae, L; Bhat, R; Cataldo, ML; De Angelis, C; Fu, X; Nanda, S; Schiff, R; Thangavel, H; Trivedi, MV; Vasaikar, S; Zhang, B | 1 |
| Agarwal, VR; Barth, RJ; Bean, JR; Chen, VS; Dillon, LM; Hosford, SR; Marotti, JD; Miller, TW; Muller, KE; Owens, P; Rosenkranz, KM; Schwartz, GN; Shee, K; Symonds, LK; Yang, W | 1 |
2 other study(ies) available for fulvestrant and Endocrine Gland Neoplasms
| Article | Year |
|---|---|
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endocrine Gland Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasm Recurrence, Local; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Receptors, Neuropeptide Y; Tamoxifen | 2022 |
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Endocrine Gland Neoplasms; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; MCF-7 Cells; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |